Q3 2026 Cencora Inc Earnings Call Transcript
Key Points
- Cencora Inc (COR) delivered strong Q3 fiscal 2026 results with double-digit adjusted operating income growth of 17% and 12% EPS growth, driven by strong execution and $1 billion in opportunistic share repurchases.
- The company raised its full-year fiscal 2026 adjusted EPS guidance to $17.75-$17.95, reflecting confidence in continued execution and portfolio strength.
- The US Healthcare Solutions segment saw strong growth, particularly in specialty across health systems and physician practices, with the OneOncology and RCA MSO platforms performing ahead of expectations.
- The International Healthcare Solutions segment delivered 21% as-reported and 23% constant-currency operating income growth, driven by strength in European distribution, World Courier, and European 3PL businesses.
- Cencora Inc (COR) is making significant progress on debt repayment, having fully paid off its $800 million RCA financing-related term loan balance, and maintains a strong cash position of $2.8 billion.
- The company's digital transformation, including the use of AI in demand forecasting, is improving operational efficiency and product availability, positioning it for long-term growth.
- Cencora Inc (COR) faces revenue headwinds from manufacturer list price reductions, which represented a $2.4 billion negative impact on US Healthcare Solutions revenue growth in the quarter.
- The company continues to experience lower sales to its large mail order customer, which was expected and consistent with the second quarter, impacting revenue growth.
- The loss of an oncology customer in 2025 continues to be a headwind, though it has now been fully lapped, and the company expects the strongest organic growth in Q4 at the midpoint of guidance.
- Net interest expense increased by $59 million year-over-year due to debt raised for the OneOncology acquisition, and is expected to be approximately $490 million for the full year, up from prior expectations.
- The pending MWI Animal Health merger with Covetrus is expected to create a $150 million operating income headwind within Other if it closes at the midpoint of fiscal 2027, with an EPS headwind of approximately $0.35.
- The company faces potential regulatory and policy uncertainties, including proposed ASP rule changes and 340B program guidance, which could impact the business, though management is assessing the potential impacts.
Hello, everyone. Thank you for joining us and welcome to the Cencora Inc Q3 fiscal year 2026 earnings call. (Operator Instructions)
I will now hand the conference over to Bennett Murphy. Bennett, please go ahead.
Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2026 third quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Mauch, President and CEO; and Eva Boratto, Executive Vice President and CFO.
On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided within today's press release, which is available on our website at investor.cencora.com. We've also posted a slide presentation to accompany today's press release on our Investor website.
During this conference call, we will discuss forward-looking statements about our business and financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
